Search company, investor...

MediQuest Therapeutics

Founded Year



Dead | Dead

Total Raised


About MediQuest Therapeutics

MediQuest Therapeutics (MediQuest) is a specialty pharmaceutical company developing first- and best-in-class topical therapies in late-stage clinical development to treat patients suffering from inflammatory and infectious diseases. Using a drug delivery technology, MediQuest can deliver a topical, non-systemic therapy through thickened or diseased skin and nails. The Company's therapeutic treatments and drug delivery have generated a robust product pipeline aimed at treating inflammatory/infectious diseases and satisfying an unmet medical need.

Headquarters Location

22322 20th Avenue South East Suite 100

Bothell, Washington, 98021,

United States


Missing: MediQuest Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MediQuest Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

MediQuest Therapeutics Patents

MediQuest Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Skin pigmentation, Dermatologic terminology, Disturbances of human pigmentation, Peptides, G protein coupled receptors


Application Date


Grant Date



Related Topics

Skin pigmentation, Dermatologic terminology, Disturbances of human pigmentation, Peptides, G protein coupled receptors



MediQuest Therapeutics Frequently Asked Questions (FAQ)

  • When was MediQuest Therapeutics founded?

    MediQuest Therapeutics was founded in 1994.

  • Where is MediQuest Therapeutics's headquarters?

    MediQuest Therapeutics's headquarters is located at 22322 20th Avenue South East, Bothell.

  • What is MediQuest Therapeutics's latest funding round?

    MediQuest Therapeutics's latest funding round is Dead.

  • How much did MediQuest Therapeutics raise?

    MediQuest Therapeutics raised a total of $39.25M.

  • Who are the investors of MediQuest Therapeutics?

    Investors of MediQuest Therapeutics include Integra Ventures, Novo Holdings, MASA Life Sciences, Janus Capital Group and Masa Inc..

  • Who are MediQuest Therapeutics's competitors?

    Competitors of MediQuest Therapeutics include Erydel, OptiNose, Cellnovo, Capnia, Intercell and 12 more.

Compare MediQuest Therapeutics to Competitors


EryDel develops a red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases. Its proprietary technology relies upon the encapsulation of drugs into red cells taken from the patient's own blood, which are then re-infused into the patient.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Global Protein Products

Global Protein Products (GPP) is a zein protein coatings company. Zein protein is the storage protein in corn kernels. It has excellent film-forming and thermoplastic characteristics.

MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.

Core Tech Solutions

Core Tech Solutions, Inc. is engaged in the development of Transdermal, Dermal and Tran mucosal Delivery Systems for the treatment of a variety of indications. The primary mission of the company is to provide transdermal drug delivery development to the worlds pharmaceutical companies. In addition to offering research and development on a contractual basis, Core Tech Solutions possesses the facilities and expertise to perform or coordinate all other aspects of commercialization including Feasibility Studies, Prototype Development, Formulation Optimization, Clinical Trials, Regulatory Compliance, Process Scale-up, and Full Scale Manufacturing.

Travanti Pharma

Transdermal delivery of drugs and cosmetic agents utilizing active-patch technology. The company was acquired by Teikoku.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.